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Abstract
The GABAB agonist baclofen has been widely researched clinically and preclinically as a
treatment of alcohol use disorders (AUDs). However, the efficacy of baclofen remains uncertain.
The clinically used racemic compound can be separated into separate enantiomers. These
enantiomers have produced different profiles in behavioral assays, with the S- compound often
being ineffective compared to the R- compound, or the S- compound antagonizing the effects of
the R- compound. We have previously demonstrated that the R(+)-baclofen enantiomer decreases
binge-like ethanol intake in the Drinking-in-the-Dark (DID) paradigm, whereas the S(-)-baclofen
enantiomer increases ethanol intake. One area implicated in drug abuse is the nucleus accumbens
shell (NACsh).The current study sought to define the role of the NACsh in the enantioselective
effects of baclofen on binge-like ethanol consumption by directly microinjecting each enantiomer
into the structure. Following bilateral cannulation of the NACsh, C57Bl/6J mice were given 5
days of access to ethanol or saccharin for 2 hours, 3 hours into the dark cycle. On Day 5 mice
were given an injection of aCSF, 0.02 R(+)-, 0.04R(+)-, 0.08 S(-)-, or 0.16 S(-)-baclofen (μg/side
dissolved in 200nl of aCSF). It was found that the R(+)-baclofen dose-dependently decreased
ethanol consumption, whereas the high S(-)-baclofen dose increased ethanol consumption,
compared to the aCSF group. Saccharin consumption was not affected. These results further
confirm that GABAB receptors and the NACsh shell are integral in mediating ethanol intake. They
also demonstrate that baclofen displays bidirectional, enantioselective effects which are important
when considering therapeutic uses of the drug.
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1. Introduction
Dopaminergic and GABAergic projections to and from the nucleus accumbens shell
(NACsh1) to areas including the ventral tegmental area (VTA) and ventral pallidus [1-4]
have been implicated in addiction. Specifically, the NACsh has been implicated in stimulant
reinforcement [5]. The “incentive arousal” view of dopamine response suggests that
accumbal dopamine is not responsible for the behavioral reaction to the stimuli, but rather
works as an amplifier signal for the stimuli – moderating whether or not the stimuli result in
a behavioral response [6]. Bassareo et al. [7] showed that ethanol and a chocolate + sucrose
tastant both elicit a dopaminergic response from the NACsh upon an animal's first
experience with the reinforcers. However, upon second presentation of the reinforcers,
although the chocolate + sucrose tastant no longer elicited a dopaminergic response, the
ethanol reinforcer elicited an even greater dopaminergic response in the NACsh.
Dopaminergic habituation to a tastant and maladaptive dopaminergic responses to drugs of
abuse have not been associated with the nucleus accumbens core (NACcore) or prefrontal
cortex (PFC)[8-10], making the NACsh a particularly important region for eliciting a
response to a drugs of abuse [6].
Ethanol interacts with GABAergic neurons of the NACsh. 80% of ethanol reactive cells in
the NACsh are GABAergic; a higher percentage than the NACcore and PFC [11]. However,
to date, few studies have attempted to alter ethanol intake in preclinical models of
consumption by manipulation of NACsh GABAergic function. Rewal et al. [12] and Nie et
al. [13] demonstrated that viral knock-down of extrasynaptic GABAA receptor subunits in
the NACsh, but not NACcore, reduced ethanol intake without affecting saccharin intake.
While these results suggest a role for GABAA receptors, GABAB receptors have not been
investigated, even though they comprise and entire third of the GABA receptors of the NAC
[14].
Baclofen, a GABAB receptor agonist used to treat severe forms of epilepsy, has been
repeatedly shown to alter ethanol consumption. Clinically, baclofen has been used to
effectively treat symptoms of alcohol use disorders (AUDs), such as craving and anxiety, in
European populations [15]. However, the results in U.S. populations have not been as
conclusive [16]. These conflicting results may be due to different alcoholic populations,
with European studies often focusing on a population of severe AUD sufferers. A U.S. study
examining hospital inpatients at a high risk for alcohol withdrawal syndrome did find
baclofen to be effective at reducing these symptoms [17].
Baclofen has also produced inconsistent results preclinically. For example, baclofen
decreased operant responding for ethanol [18, 19], lowered the breakpoint for ethanol in
alcohol preferring rats [20], and decreased intake of ethanol [21, 22] when administered
systemically. Baclofen also decreased binge-like ethanol consumption when microinjected
directly into the anterior, but not posterior, VTA [23]. Conversely, baclofen has also been
1Artificial cerebrospinal fluid (aCSF), Alcohol use disorders (AUDs), Blood ethanol concentration (BEC), C57Bl/6J (B6), Drinking-
in-the-Dark (DID), High Alcohol Preferring (HAP), nucleus accumbens core (NACcore), nucleus accumbens shell (NACsh),
prefrontal cortex (PFC), ventral tegmental area (VTA)
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demonstrated to increase ethanol consumption following acute and chronic systemic
injections [24-26].
The baclofen that is used clinically is a racemic compound that breaks down into absolute
configurations of R- and S- and positive (+) and negative (-) molecular rotations. We have
observed enantioselective effects of baclofen on the binge-like ethanol consumption
produced by Drinking-in-the-Dark (DID); R(+)-baclofen reduced drinking whereas S(-)-
baclofen increased drinking (Kasten et al., submitted). Enantioselective effects of baclofen
have also been demonstrated in other behavioral paradigms, with R-baclofen often being
more behaviorally active. Olpe et al. [27] quantified the effects of R-, S-, and racemic
baclofen on reflexes and electro-shock seizures. S- was completely ineffective, even at the
highest dose, whereas R- was equally effective as the racemic compound. Paredes and
Agmo [28] demonstrated that S(-)-baclofen was ineffective at inhibiting sexual behavior,
whereas R-baclofen was twice as effective as the racemic compound. S-baclofen has been
demonstrated to depress the trigeminal nucleus oralis response, but at a dose 20 times larger
than the least effective R-dose [29]. In the periphery, S-baclofen reduced the response to R-
baclofen [29]. While Olpe et al. [27] suggest that S-baclofen may play a role in potentiating
the action of R-baclofen without being active itself, Fromm et al. [29] show that S-baclofen
is not only active at higher doses, but that it also may inhibit the actions of R- in certain
cases. Collectively, these studies show that the behavioral effects of baclofen are enantiomer
dependent, and highlight the importance of considering enantioselective aspects of drug
effects when accounting for the therapeutic use of the drug [30].
A second aspect of considering therapeutic potential is choosing an appropriate model of
behavior to test the drug [29]. One of many such models is DID, which has been used
extensively in our lab to test drug treatments via systemic and microinjection approaches
[23, 31-33]. Developed by Rhodes et al. [34, 35], DID achieves high levels of binge-like
drinking by introducing ethanol three hours into the dark cycle with a two hour access
period. In a relatively short period of time, B6 mice reliably ingest enough ethanol to reach
pharmacologically relevant BECs of over 1mg/ml without introducing food or water
restrictions. As such, DID presents a simple model that can be used to screen potential AUD
treatments that target various receptor systems, including the GABA, endocannabinoid,
glutamate, and dopamine receptor systems [23, 32, 36].
We hypothesize that microinjection of R(+)-baclofen into the NACsh will reduce ethanol
intake, but that microinjection of S(-)-baclofen will increase ethanol intake, in the binge-like
DID paradigm. Further, we hypothesize that microinjection of baclofen into the NACsh will
not affect saccharin intake, as the NACsh no longer releases dopamine in response to a
second exposure to a saccharin reinforcer [7].
2. Method
2.1 General Design
In brief, male B6 mice underwent surgery for bilateral cannulation of the NACsh. Following
at least 48 hours of recovery, mice began a five-day DID procedure where 20% ethanol or
0.2% saccharin was available for two hours, three hours into the dark period each day. On
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Day 5, animals received one of five possible microinjection doses; 0.02 or 0.04μg R(+)-
baclofen, 0.08 or 0.16μg S(-)-baclofen, or artificial cerebrospinal fluid (aCSF) (Fig. 1).
2.2 Subjects
Male B6 mice were bred in-house. Breeders for our colony were obtained from Jackson
Laboratory (Bar Harbor, ME) and replaced every few months by new breeder pairs
purchased from Jackson Laboratory. A total of 118 animals were used in this study. One
aCSF control group (dose = 0.0 μg) was used for each reinforcer (ethanol or saccharin) to
reduce the number of animals associated with this project (see Fig. 1).
Animals received food at all times and water ad lib apart from during implementation of
DID. Lights were kept on a reverse light-dark schedule with lights off at 8am. Animals were
group housed until the time of surgery, after which time they were individually housed.
Animals were at least 58 days of age at the time of surgery, and at least 60 days of age at the
time DID was initiated. Procedures were approved by the IUPUI School of Science
Institutional Animal Care and Use Committee and conformed to the Guide for the Care and
Use of Laboratory Animals (The National Academic Press, 2003).
2.3 Drugs
Ethanol (190 proof) was obtained from Pharmco, Inc (Brookfield, CT). The 20% v/v ethanol
solution was prepared with tap water. Saccharin (≥99%) was obtained from Sigma Aldrich
(St. Louis, MO) and was dissolved in tap water to make a 0.2% saccharin solution. R(+)-
and S(-)-baclofen was obtained from Sigma Aldrich (St. Louis, MO). Baclofen was
dissolved in aCSF (Sigma Aldrich, St. Louis, MO) to doses of 0.02 and 0.04 μg for R(+)-
baclofen, and 0.08 and 0.16 μg for S(-)-baclofen. Unadulterated aCSF was used as the 0.0 μg
control group. Drug was delivered in a volume of 200 nl per side at a flow rate of 382 nl/
min.
Drug doses were chosen with the goal of finding the highest dose that did not affect ethanol
intake, as well as the lowest dose that did cause an effect on ethanol intake for each
enantiomer. Initial R(+)-baclofen doses for this study were based on those previously used
by our lab [23,47]. Pilot doses of 0.01, 0.02, and 0.04 μg of R(+)-baclofen suggested that
0.04 μg/side would be the lowest dose to reduce ethanol intake, whereas 0.02 μg/side would
be the highest dose that would not affect intake. S(-)-baclofen doses were expected to be
higher than R(+)-baclofen doses, because S(-)- is the less potent enantiomer. Piloting
appropriate doses for S(-)-baclofen began by using a high dose of 0.32 μg/side. This dose
appeared to incapacitate the animals, and was therefore cut in half to 0.16 μg/side. The 0.16
μg/side appeared to potentially increase drinking in the pilot group, and was kept as one of
the two final doses. To choose the second final dose, 0.08 μg/side and 0.24 μg/side doses
were piloted. The 0.24 μg/side did not appear to increase ethanol intake more than the 0.16
μg/side dose, therefore the 0.08 μg/side dose was chosen because it appeared to be the
highest dose that would not affect intake. All pilot groups had an n=3. Mice that were used
to pilot successful doses were included in the final analyses.
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2.4 Surgery
The NACsh was targeted (coordinates of ML: ±0.63, AP: 1.18, DV: 2.0) by bilateral
cannulation. Surgical procedures followed those currently outlined in our approved IACUC
protocol. Detailed surgical procedures are described in our previous publications [23, 32,
33].
2.5 DID Procedures
Following surgery, animals had at least 48 hours of recovery before initiation of DID.
During the recovery time, the cannula stylets were removed daily to prevent obstruction.
Although daily restraint was necessary to remove the stylets, timed restraint to habituate the
animal to the microinjection procedure began on Day 3 of DID. Stylet removal and restraint
occurred immediately prior to the bottles-on time to acclimate animals to any restraint stress
associated with the microinjection procedure.
DID procedures were slightly modified from that of Rhodes et al. [34, 35] and Moore et al.
[31]. Three hours into the dark cycle animals received two hours of access to either a 20%
ethanol solution or a 0.2% saccharin solution in 10mL ball-bearing sipper tubes for five
days, with access to only water for the remaining 22 hours. The saccharin group was
included as a control group for drug effects on alternative reinforcers. Fluid leak was
monitored by recording fluid levels of bottles placed on empty cages on the animal rack.
Fluid levels were recorded to the level of 0.05 mls.
Restraint took place on Day 3 and mock microinjections took place on Day 4. The mock
microinjection procedure consisted of removing the stylets and inserting mock
microinjectors into the cannula. The mock injectors reached 1mm into the brain beyond the
end of the cannula. They were held in place for one minute to mimic the microinjection
procedure. Drug was administered via microinjection on Day 5. R(+)-baclofen was
microinjected with the hypothesis that it would reduce ethanol consumption. S(-)-baclofen
was microinjected with the hypothesis that it would increase ethanol consumption. On Days
1-3, fluid volumes were recorded immediately before and after fluid access. On Days 4 and
5, fluid volumes were recorded immediately before and after fluid access, as well as every
20 minutes during fluid access to capture the time course of the drug effects on Day 5.
2.6 Intra-NACsh Microinjections
Details on construction of guide cannulae, stylets, and microinjection tubing as well as the
microinjection procedure are detailed in our previous publications [23, 32, 33].
2.7 Blood Ethanol Concentrations
Immediately following ethanol access on day 5, retro-orbital sinus blood samples were
collected using 50 μL heparinized microcapillary tubes. Samples were immediately placed
in the centrifuge and plasma and decanted. The samples were stored at −80°C until time of
assay, at which point they were analyzed for ethanol content using an Analox Alcohol
Analyzer (Analox Instruments, Lunenburg, MA).
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2.8 Histological verification of Cannulae Placement
Immediately following the end of drinking on Day 5, animals were euthanized by cervical
dislocation and brains were extracted and flash-frozen using methylbutane (−25°C). Brains
were stored in the −20°C freezer until they were sliced using a cryostat, thaw-mounted on
slides, thionin stained, and cover slipped. Placement of cannulae was inspected and verified
by two different experimenters that were blind to the dose of baclofen given and amount of
reinforcer consumed. A representative bilateral hit of the NACsh is shown in Fig. 2.
2.9 Statistical Analysis
Statistical analyses only included animals that made it through all five days of drinking and
that had histologically verified bilateral hits of the NACsh. Final sample sizes were N = 44
(84.62% hit rate) for the ethanol analyses and N = 42 (85.71% hit rate) for the saccharin
analyses. Ethanol and saccharin results were analyzed separately. Within the ethanol and
saccharin groups, R(+)- and S(-)-baclofen were analyzed together because they shared a
control group. Significance level for all overall analyses was set at p < .05, with all post-hoc
tests corrected for multiple comparisons.
Drinking acquisition on Days 1-4 was assessed using a one-way analysis of variance
(ANOVA) with day as the within-subject factor. Tukey's post-hoc tests were used when
warranted. A one-way ANOVA was used to analyze total Day 4 drinking with treatment as
the between-subjects factor to verify that total baseline drinking following mock
microinjection did not vary between groups. Following this verification, treatment effects on
total Day 5 drinking were assessed using a one-way ANOVA with treatment as the between-
subjects factor. For the ethanol animals, a one-way ANOVA with treatment as the between-
subjects factor was also used to assess dose effects on BEC following intake, and a bivariate
Pearson's correlation was used to compare total intake to BEC. Independent samples t-tests
were used for all necessary post-hoc tests on total 2hr consumption and BEC data. Post-hoc
tests were corrected for multiple comparisons for each drug dose compared to the control.
To compare time course of intake on micro- versus mock-injection day, a two-way repeated
measures ANOVA with Day and Time-Bin as within-subjects factors for each treatment
group independently was used. Paired samples t-tests were used as post-hoc tests for
repeated measures analyses. To assess for treatment-effects on time course of intake, a two-
way repeated measures ANOVA with treatment as the between-subjects factor and time as
the within-subjects factor was used. Day 4 intake was assessed first to verify that there were
no baseline differences in time course between each dose group. Following this verification,
Day 5 data was assessed. One-way ANOVAs were used at each time-point with treatment as
the between subjects factor as post-hoc tests for a significant two-way ANOVA. Tukey's
post-hoc tests were used for any significant one-way ANOVA effect.
3. Results
3.1 Ethanol Consumption
The ANOVA on Days 1-4 acquisition of drinking revealed a significant effect; F(3,175) =
3.21, p < .05 (Fig. 3A). Tukey's post-hoc revealed that Day 2 drinking was significantly
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higher than Day 3 drinking (p < .05). Total Day 4 drinking following the mock injection did
not differ between groups; F(4,43) = .322, p > .05, data not shown. There were significant
treatment effects on total Day 5 ethanol intake following the microinjection; F(4,43) =
10.14, p < .001. Independent samples t-tests corrected for multiple comparisons for each
treatment to the aCSF group revealed that the 0.04 μg R(+)-baclofen group drank
significantly less than the aCSF group, whereas the 0.16 μg S(-)-baclofen group drank
significantly more than the aCSF group (p's < .05) (Fig. 3B). This pattern was replicated in
the BEC data, with the 0.04 R(+)-baclofen group showing significantly lower BECs than the
aCSF group, while the 0.16 S(-)-baclofen group showed significantly higher BECs
immediately following ethanol intake (p's < .05) (Fig. 3C). BECs and total two hour ethanol
consumption were strongly correlated; r(43) = 0.834, p < .001 (Fig. 3D).
The time course of ethanol intake was then statistically compared. For both analyses,
Greenhouse-Geisser statistics are reported because Mauchly's Test for Sphericity was
significant (p's < .05). A treatment*time bin repeated measures ANOVA on Day 4 time
course intake verified that there were no baseline differences between dose groups; F(11.38,
110.90) = 1.169; p > .05, data not shown. The time course of ethanol intake following
micro-injection on Day 5 was significantly different between treatment groups; F(16.12,
153.18) = 1.931, p < .05. One-way ANOVAs at each time-point revealed that differences
between treatment existed at the 1-20, 81-100, and 101-120 minute time bins (p's < .05).
Tukey's post-hoc tests revealed that at 1-20 minutes, the 0.04 μg R(+)- group drank
significantly less than the aCSF group (p < .05). At 81-100 minutes, the 0.16 μg S(-)- group
drank significantly more than the 0.02 and 0.04 μg R(+)-groups (p's < .05). At the 101-120
minute time point, the 0.16 μg S(-)- group drank significantly more than the aCSF, 0.02, and
0.04 μg R(+)- groups (p's < .05) (Fig. 4A).
Repeated measures ANOVAs comparing the time course of drinking on Days 4 and 5 for
each dose independently were used to systematically assess the treatment effect of the
microinjection on drinking. These analyses revealed no main effects of time or day, nor was
there an interaction for the aCSF and 0.16 S(-)- groups (p's > .05) (Fig. 4B & 4F). However,
the 0.02 R(+)- group showed a main effect of day and time, with animals drinking less on
the microinjection day and drinking being lower in the middle of the drinking session (p's < .
05). There would have been an effect of day*time bin, except Mauchly's Test for Sphericity
was significant (p = .049) and Greenhouse-Geisser statistics indicated no interaction was
present; F(1.99,15.918) = 2.99, p = .079 (Fig. 4C). There was also a main effect of day for
the 0.04 R(+)-group, with animals drinking less overall on the microinjection day (p < .05).
There was no main effect of time (p >.05). Again, a significant interaction of Day*Time bin
was reduced by a significant Mauchly's Test for Sphericity (p < .05), with the Greenhouse-
Geisser correction only trending towards significant; F(1.858,13.077) = 3.591, p = .06 (Fig.
4D). Analysis of the 0.08 S(-)- data only revealed a significant main effect of time, with
higher drinking in the first (1-20) and last (101-120) 20 minute bins (p < .05). There was
also an interaction of day*time; F(5,40) = 3.635, p < .01. Post-hoc paired samples t-tests
revealed that drinking on the microinjection day was significantly lower only at the 1-20
minute point; t(8) = 4.218, p < .01 (Fig. 4E).
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3.2 Saccharin Consumption
The ANOVA on Days 1-4 acquisition data revealed no significant effect of day on
acquisition of drinking; F(3,45) = 2.206, p > .05 (Fig. 5A). Total two-hour saccharin
drinking on Day 4 revealed no baseline differences in drinking between treatment groups;
F(4,41) = 2.043, p > .05, data not shown. There were no effects of drug treatment on total
Day 5 drinking; F(4,41) = 0.981, p > .05 (Fig 5B).
The time course of saccharin intake was then statistically compared using a two-way
repeated measures ANOVA on Days 4 and 5. There were no baseline differences in the time
course of saccharin intake on Day 4; F(13.85,128.14) = 1.194, p > .05, data not shown.
Further, there were no differences in time course of intake on Day 5; F(14.89,137.74) =
1.096, p > .05 (Fig. 6A). Greenhouse-Geisser statistics are reported for both of these
repeated measures ANOVAs, as Mauchly's Test of Sphericity was significant for each test
(p's < .01).
Next, the time course of Day 4 saccharin drinking was compared to that on Day 5. Analysis
of the aCSF data revealed significant main effects of day and time on drinking (p's < .05),
with consumption being lower on Day 5, and drinking being lower as time went on (Fig.
6B). There was no interaction between day*time bin (p > .05). Analysis of 0.02 R(+) data
showed no effect of day or an interaction of day*time, but did find a main effect of time (p
< .05) (Fig. 6C). No main effects or interactions were found for the 0.04 R(+)- group (p's > .
05) (Fig. 6D). Analysis of 0.08 S(-)- and 0.16 S(-)- data revealed only a main effect of day
(p < .05), with animals consuming less saccharin following the microinjection versus the
mock injection (Fig. 6E and 6F, respectively).
4. Discussion
Overall, these data show that intra-NACsh microinjection of R(+)- and S(-)-baclofen
bidirectionally alter ethanol, but not saccharin intake. Total ethanol intake is decreased by
the high dose 0.04 μg R(+)-baclofen/side, but increased following microinjection of the high
dose 0.16μg S(-)-baclofen /side. These drug effects also show a distinct time course of
action, with R(+)-baclofen reducing ethanol intake early compared to aCSF, but S(-)-
baclofen increasing ethanol intake later compared to aCSF. It is nevertheless important to
note that although the high R(+)-baclofen treatment trended towards an interaction, the high
R(+)- and S(-)-baclofen treatments did not show time-specific effects in the within-groups
analyses (Fig. 4D and 4F, respectively). Moreover, although ethanol and saccharin animals
did not show statistically significant difference in time-course of intake on Day 4, they were
not matched to Day 5 treatment group by time-course of intake. Thus, for a clearer
interpretation of time-course of drug effects, future studies should match treatment groups
by both total intake and time-course of intake. Saccharin intake was not affected by either
baclofen enantiomer. Therefore, the current results are not likely an artifact of alterations in
locomotor activity following drug administration. This point is especially well documented
in that the high R(+)-baclofen dose did not reduce saccharin intake compared to the mock
injection day, although aCSF injection did (Figs. 6D and 6B, respectively).
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4.1 Effect of the Microinjection
As demonstrated in the mock- versus microinjection time course data, the microinjection of
aCSF did not reduce ethanol consumption compared to the mock injection day, suggesting
that the reduction of ethanol consumption in the high R(+)-baclofen dose group was a drug
effect, and not simply an aversive response to the microinjection. Conversely, the aCSF
microinjection did reduce saccharin intake compared to consumption following the mock
injection. These data may suggest that the aCSF injection reduced the motivation of the mice
to consume saccharin, and that B6 mice may be more motivated to consume ethanol than
saccharin following an aversive experience, which has been previously demonstrated.
Aversive shock stimuli have been shown to increase ethanol consumption [37, 38], whereas
chronic mild stressors inhibit development of conditioned place preference for sucrose [39],
as well as decrease sucrose and saccharin intake [40, 41]. Intake of the sweet reinforcers was
recovered using a tricyclic antidepressant, but this effect was blocked when dopamine
antagonists were concurrently administered [40]. As discussed in section 1 and further in
section 4.4, the NACsh and dopamine of the NACsh are integral parts of motivation to
obtain a reinforcer [6]. The presence of dopamine in the NACsh following ethanol
presentation [7] may have reduced the aversive consequences of the microinjection
procedure, leading animals to continue consuming ethanol at their previous drinking rates,
whereas the saccharin animals reduced consumption.
4.2 Locomotor Sedative Effects of Baclofen
In our experience, ethanol consumption and locomotion do not exhibit the same behavioral
pattern. Within the DID paradigm, home cage locomotion markedly decreases by the 14th
day of ethanol access, whereas ethanol consumption remains stable [42]. Moreover,
baclofen is typically thought of as possessing sedative properties. Cryan and colleagues [43]
demonstrated that baclofen potentiates locomotor sedation in naïve animals when
systemically administered. However, Spano et al. [44] established that systemic
administration of baclofen reduced reinstatement of heroin-seeking behavior in rats re-
exposed to heroin, without affecting inactive lever presses or locomotor activity. Further,
Agmo and Paredes [45, 46] demonstrated that while baclofen reduced sociosexual behavior
and locomotion, other drugs also decreased locomotion without affecting sociosexual
behavior, suggesting that reductions in locomotor activity are not causative of reductions in
motivated behavior. Using home-cage locomotor activity boxes, our lab has recently
demonstrated that systemic administration of R(+)- and S(-)-baclofen do not alter locomotor
activity during ethanol or saccharin consumption in the same 5 day DID paradigm used in
the current study [47]. Thus, our results, taken with those of Spano et al. and Agmo and
Paredes, suggest that baclofen is working to reduce ethanol consumption via mechanisms
alternative to those producing sedation.
4.3 Stereospecific Drug Action
The major highlight of these results is the stereospecific, bidirectional effects of the baclofen
enantiomers on ethanol intake when microinjected into the NACsh. One explanation of this
result may be differential binding. Other molecules, such as type 1 antiarrhythmic drugs and
rolipram exhibit stereospecific binding that is related to molecular rotation of the molecule
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and differing binding affinity [48, 49]. In the case of rolipram, the high affinity binding sites
mitigate the antidepressant effects of the drug [50]. Mecamylamine, a nicotinic
parasympathetic ganglionic blocker that has been investigated for treating AUDs, also
shows stereospecific binding which appears to be related to differing outcomes in behavioral
assays [51].
As such, the actions of baclofen may depend on whether high and low affinity GABAB
receptors exist, whether R(+)- and S(-)-baclofen binding is preferential to one type of
receptor over the other, and whether this affinity, sensitivity, or binding preference is related
to behavioral effects of the drug. Binding of baclofen relies not only on the absolute
configuration of the drug (d/l or S/R), but also on the rotation of the molecule (+ or -). Both
R- and S-baclofen are equally efficacious in displacing GABA from high and low affinity
binding sites, but (-)baclofen is much more efficacious than (+)baclofen at displacing
racemic baclofen at low affinity sites, which appear to be selective for (-)baclofen [52-54].
Further, these enantiomers interact differently with other neurotransmitters. Karbon and
colleagues [55] suggest that the (-)baclofen isomer interacts with norepinephrine, whereas
Waddington and Cross [52] suggest that non-GABAergic effects of baclofen lie with the R-
configuration.
These literature sources suggest that the R- absolute configuration and the (-) molecular
rotation are important for binding affinity and interaction with other receptor systems in the
brain. Yet, the mixtures used in this study combine the R- configuration with the (+)
rotation, and the S- configuration with the (-) rotation, leading to an extremely muddled
interpretation of binding and affinity results. In B6 mice, it can be surmised that there is a
representation of GABAB receptors that are susceptible to both R(+)- and S(-)-baclofen in
the NACsh. The increased ethanol consumption following S(-)-baclofen microinjection may
be related to low affinity binding sites that are selective for (-)-baclofen, whereas decreased
ethanol consumption following R(+)-baclofen may be related to sites that are selective for
that baclofen molecule, or the interactive effects of R-baclofen on non-GABAergic
mechanisms. As B6 mice are an inbred strain, they represent an isogenic population that
may not offer the ability to see individual differences in response to each enantiomer of
baclofen, although their ethanol intake may be quite variable. As such, it is possible that
individual differences in receptor subtypes leads to the differences of baclofen efficacy
reported in human literature [56], or that increased severity of AUDs leads to neuroadaptive
changes that cause an individual to be more susceptible to the R-baclofen enantiomer. It may
therefore be of interested to assess the enantioselective effects of baclofen in an animal
model that represents a homozygous population, such as the selectively bred High Alcohol
Preferring (HAP) lines [57].
4.4 Neurotransmitter Involvement
Involvement of different neurotransmitter systems may explain why intra-NACsh baclofen
altered ethanol, but not saccharin intake. Ethanol, but not saccharin, is known to interact
with GABAA receptors. Extrasynaptic GABAA receptor subunit knock down has been
demonstrated to reduce ethanol intake, but not saccharin intake [12, 13]. As previously
discussed, the NACsh has been deemed an area of maladaptive dopamine release in
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response to drugs of abuse [6]. Considering the work done by Bassareo et al. [7, 10], it is
possible to conclude that by the fifth day of ethanol access compared to the first day of
access, the NACsh is releasing greater amounts of dopamine. Whereas it can be concluded
that there is no release of dopamine in response to saccharin presentation on the fifth day of
access in the NACsh, dopamine is still released in the NACcore and PFC. Furthermore, the
GABA and dopamine systems of the NAC are known to interact; dopaminergic terminals
are located on GABAergic neurons and form junctions with GABAergic dendrites, and
dopamine agonists inhibit GABA release in the NAC [58-60]. Therefore, the effects of
baclofen on ethanol, but not saccharin, intake may be contingent upon the presence of
GABA and/or dopamine in the NACsh that would be released in response to the
presentation of the ethanol reinforcer. Evidence of this has been shown in the VTA, where
baclofen microinjection reduced microdialysate dopamine [61] and reduced binge-like
ethanol intake in the DID paradigm when injected into the anterior VTA [23]. The role of
dopamine release on reinforcer intake would be further implicated if microinjection of
baclofen into the NACcore or PFC on the fifth of saccharin intake altered saccharin
consumption.
4.5 Neurocircuitry
There are reciprocal efferent and afferent GABAergic and dopaminergic projections to and
from the NACsh. GABAergic efferents from the NACsh project to the ventral pallidum and
the VTA [2, 3]. Both of these areas are believed to be involved in reinforcer-directed
behavior. Lesions of the ventral pallidum reduce development of conditioned place
preference and decrease self-administration of reinforcers and drugs of abuse [62, 63].
Approximately 35-55% of the projections from the NACsh to the VTA are GABAergic
projections, and these projections synapse on both dopaminergic and non-dopaminergic
neurons of the VTA, including GABAergic interneurons which function to disinhibit VTA
dopamine neurons [3]. The dopaminergic feedback loop between the NACsh and VTA is
also considered to be especially important, with the NAC receiving dopaminergic afferent
projections to its GABAergic cells [1]. This projection has been implicated as playing a role
in the reduction of ethanol intake observed following microinjections of baclofen in to the
anterior VTA [23]. The current results suggest that the reciprocal NACsh-to-VTA projection
is also playing an important role in modulating ethanol intake. Further, projections to the
VTA and ventral pallidum may also be involved in the motivation to consume the reinforcer
or the perceived value of the reinforcer, and baclofen may be altering how the NACsh is
communicating with these areas as well.
When discussing the neurocircuitry considerations of microinjection studies, it is important
to note possible drug diffusion outside of the target brain area. The 200 nl/side of fluid
injected in the current study is less than what has been injected into the NACsh in previous
studies [64, 65]. A built-in control for determining diffusion is histological misses. In the
present study, the high R(+)- and high S(-)-baclofen treatments each had a miss-rate of n=2
in the ethanol animals. In these animals, the microinjector tips bilaterally hit the NACcore.
These animals showed no drug effect on ethanol consumption, which replicates previous
lack of effects on ethanol consumption following GABAergic modulation in the core
[12,13]. Further, our lab has previously shown anatomical specificity of baclofen when
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microinjected into the VTA at the same fluid volume given in the current study. Moore &
Boehm [23] demonstrated that baclofen injected into the anterior, but not posterior, VTA
reduced ethanol consumption. As such it is possible to infer that the fluid volume given does
not diffuse so widely, as the VTA is a much smaller anatomical structure than the nucleus
accumbens.
4.6 Drawbacks to DID
When interpreting the differences between drug effects on ethanol and saccharin intake, it is
important to keep in mind that DID only accounts for consumption of the reinforcer, but not
the reinforcer value. This poses a problem for assessing whether the chosen reinforcers,
ethanol and saccharin, are similarly reinforcing and whether drug effects are truly reinforcer
specific, or if they are due to increased motivation to obtain saccharin. While mice freely
ingest saccharin and a 0.2% solution is often used as a standard reinforcer control group
[66-68], minimal data exists on the reinforcing quality of different saccharin concentrations
as seen in operant paradigms. One study [67] found that animals responded 2.5 times more
in an FR4 operant paradigm for a 0.2% w/v saccharin solution than a 20% v/v ethanol
concentration.
At a 0.2% w/v concentration, B6 mice have between a 50% to a 94.5% saccharin preference
[66, 68]. As seen in Risinger et al. [67], similar preference does not mean animals will work
to similar amounts to obtain the reinforcer. Although 0.2% saccharin and 20% ethanol have
similar preference ratios, yet B6 mice work 2.5 times harder to receive saccharin. Working
to overcome negative drug effects to consume saccharin would explain why animals drank
even after receiving R(+)-baclofen, but it does not explain why S(-)-baclofen did not
produce an increase in saccharin consumption or why aCSF reduced saccharin intake.
Further, our lab has observed reductions in saccharin intake following systemic R(+)-
baclofen [47], so concluding that R(+)-baclofen is unable to reduce saccharin consumption
would seem unsatisfactory. Perhaps, the best explanation is that the NACsh is not
responsible for the control of saccharin intake, likely due to a combination of a transfer of
control to another brain region and the possible lack of dopamine response on Day 5. This
hypothesis could be tested by microinjecting baclofen into different brain regions or at
different time-points.
4.7 Conclusion
The hypothesis that R(+)- and S(-)-baclofen would bidirectionally alter ethanol intake, but
not saccharin intake, was upheld. It is not likely that the effects of baclofen on
consummatory behavior were related to locomotion, as baclofen did not alter saccharin
intake. Overall, GABAergic interactions with dopamine in the NACsh may have contributed
to the drug effects seen in this study. Maladaptive dopamine release in the NACsh occurs
with consumption of drugs of abuse, like ethanol, but not to simple tastants, like saccharin.
This maladaptive dopamine release may be necessary for altering consummatory behavior,
explaining the lack of drug effect on saccharin intake. When administered systemically,
R(+)-baclofen reduces saccharin intake. Systemic administration presumably allows these
drugs to act elsewhere, like the NACcore or the PFC where there is still release of dopamine
in response of the tastant.
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The stereospecific effects of baclofen on ethanol intake may be related to a myriad of
enantioselective properties like those seen in other compounds. These include differential
binding to high/low affinity receptors which may influence differential receptor effects or
which behaviors receptors may modify. Overall, these results continue to support the
important role of the GABAB receptor in the modulation of ethanol intake. They also
reinforce the notion that drugs exert enantioselective actions on behaviors, and that these
actions are extremely important in considering the efficacy or potency of a drug for clinical
treatment. Enantioselective effects may indeed help explain the inconsistent results reported
in the human literature on the use of baclofen for the treatment of AUDs.
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Highlights
• R(+)- and S(-)-baclofen were microinjected into the nucleus accumbens shell.
• Binge-like ethanol and saccharin intake were monitored.
• Time-course of ethanol and saccharin intake was monitored.
• We report a bidirectional, enantioselective effect on binge-like ethanol intake.
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Figure 1.
Study design.
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Figure 2.
Histological representation of accurate cannulae placement in the nucleus accumbens shell.
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Figure 3.
Microinjection of R(+)- and S(-)-baclofen into the NACsh bidirectionally affects ethanol
consumption. A) Acquisition of ethanol drinking. B) Total two hour ethanol consumption is
reduced by a 0.04 R(+)-baclofen dose, but increased by a 0.16 S(-)- baclofen dose compared
to an aCSF microinjection. C) This bidirectional effect is also represented in the BECs
immediately following intake on Day 5. D) BECs were strongly and significantly correlated
with total ethanol intake. Asterisk (*) indicates significantly different than the aCSF group at
p < .05. Asterisk (***) indicates significantly different than the aCSF group at p < .001. n's
= 8-9 per group.
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Figure 4.
Time-course of ethanol intakes. A) Following the microinjection, the time course of ethanol
intake was significantly different between dose groups. Asterisk (*) indicates a significant
post-hoc ANOVA at that time point, p < .05. Time course of ethanol intake following the
mock and microinjections for the aCSF (n=8) (B), R(+)- 0.02 (n=9) (C), R(+)- 0.04 (n=9)
(D), S(-)- 0.08 (n=9) (E), and S(-)- 0.16 (n=9) (F) groups. Asterisk (*) indicates a significant
difference between the mock and microinjection intake at that time point, p < .05. Plus sign
(+) indicates a main effect of time, p < .05. Ampersand (&) indicates a main effect of day, p
< .05.
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Figure 5.
Effects of microinjection of R(+)- and S(-)-baclofen in the NACsh on saccharin intake. A)
Acquisition of saccharin intake. B) Microinjections of R(+)- and S(-)- baclofen do not alter
ethanol intake compared to a microinjection of aCSF (n's = 7-10 per group).
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Figure 6.
Time-course of saccharin intakes. A) Following the microinjection, the time course of
saccharin intake was not significantly different between dose groups. Time course of
saccharin intake following mock and microinjections for the aCSF (n=9) (B), R(+)- 0.02
(n=7) (C), R(+)-0.04 (n=8) (D), S(-)- 0.08 (n=10) (E), S(-)- 0.16 (n=8) (F) groups. Plus sign
(+) signifies a main effect of time, p < .05. Ampersand (&) signifies a main effect of day, p
< .05.
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